According to the latest Annual Global Survey by the World Federation of Hemophilia in 2023, there are 809 hemophilia patients ...

Driven by Biopharmaceutical Innovations and Gene Therapies, the market Booms Amidst Growing Incidence of Hemophilia and Von Willebrand Disease ...

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?

Credit: skipper_sr/Shutterstock. Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and hypophosphatasia. New investor Nextech ...

A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with hemophilia A, the most common form of hemophilia. The research team was able to show ...

Look closely at this image, stripped of its caption, and join the moderated conversation about what you and other students see. By The Learning Network Look closely at this image, stripped of ...

Hemophilia is a rare disorder in which a person’s blood is not able to clot properly, resulting in unusually easy and prolonged bleeding. Within the blood, proteins called clotting factors normally ...

Administered via daily subcutaneous injections, Alhemo is approved in the U.S. to prevent or reduce the frequency of bleeding episodes in people with hemophilia A or B, ages 12 and older, with ...

Prompt diagnosis and treatment are critical as DI can cause substantial morbidity and mortality. The gold standard for diagnosis is a water deprivation test followed by desmopressin administration.

If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today. In fact, in the 1950s and 1960s, life expectancy for the disease was around ...

Anchoring the west side of Indianapolis, the White River State Park offers 250 acres of green space dotted with memorials and museums as the Central Canal and the White River offer waterways in ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...